source
- FDA releases weekly update on user fee letters and new HHS regulatory agendaThe FDA's latest weekly briefing highlighted the release of user fee commitment letters, which outline the agency's financial planning for upcoming fiscal periods. It also introduced a new regulat…
- FDA grants accelerated approval to Bristol Myers' iberdomide for relapsed or refractory multiple myelomaThe U.S. Food and Drug Administration has issued an accelerated approval for iberdomide, a small-molecule therapy developed by Bristol Myers Squibb. The approval targets patients with multiple mye…